Community acquired pneumonia resident survival guide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Overview

A lower respiratory tract infection in a previously normal individual acquired through normal social contact rather than contracting it in a hospital. Community-acquired pneumonia (CAP) is a disease in which individuals who have not recently been hospitalized develop an infection of the lungs. CAP is a common illness and can affect people of all ages. It often causes problems like dyspnea, fever, chest pain, and cough. CAP causes fluid accumulation in the alveoli leading to poor gas exchange. CAP is common worldwide and is a leading cause of illness and death. Causes of CAP include bacteria, viruses, fungi, and parasites. CAP can be diagnosed by history and a physical examination alone, though x-rays, sputum examinations, and other diagnostic tests are often used. As CAP is often bacterial, the primary empiric treatment consists of wide-spectrum antibiotics. Some forms of CAP, such as pneumococcal pneumonia may be prevented by vaccination.

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Complications of community acquired pneumonia, such as pleural effusion, lung abscess, bacteremia and septicemia are life-threatening conditions and must be treated as such irrespective of the causes.

Common Causes

Following are the causes listed according to the microbiological etiology

• Typical Bacteria

1. Streptococcus pneumoniae
2. Haemophilus influenzae
3. Escherichia coli
4. Klebsiella pneumoniae
5. Pseudomonas aeruginosa

• Atypical Bacteria

1. Mycoplasma pneumoniae
2. Chlamydophila pneumoniae
3. Legionella pneumophila

• Viruses

1. Influenza
2. Parainfluenza
3. Respiratory syncytial virus (RSV)
4. Metapneumovirus
5. Adenovirus

Following are the causes listed according to the the location of the patient

• Outpatient

1. Streptococcus pneumoniae
2. Mycoplasma pneumoniae
3. Haemophilus influenzae
4. Chlamydophila pneumoniae
5. Influenza A and B, adenovirus, respiratory syncytial virus, parainfluenza

• Inpatient (non-ICU)

1. Streptococcus pneumoniae
2. Mycoplasma pneumoniae
3. Haemophilus influenzae
4. Legionella
5. Aspiration
6. Influenza A and B, adenovirus, respiratory syncytial virus, parainfluenza
7. Yersinia enterocolitica

• Inpatient (ICU)

1. Streptococcus pneumoniae
2. Staphylococcus aureus
3. Legionella
4. Gram-negative bacilli
5. Haemophilus influenzae
6. Acinetobacter baumannii

Management

Shown below is an algorithm depicting the management of community acquired pneumonia according to the Infectious Diseases Society of America (IDSA) and Thoracic Society Consensus Guidelines on the Management of Community Acquired Pneumonia in Adults.

Characterize the symptoms: ❑ Fever ❑ Cough ❑ Sputum production ❑ Dyspnea ❑ Pleuritic chest pain ❑ Confusion most prominently in the elderly ❑ Shaking chills

Examine the patient: ❑ Vital signs ❑ Temperature ❑ Respiratory rate ❑ Heart rate ❑ Blood pressure ❑ Pulse oximetry ❑ Respiratory examination: ❑ Decreased expansion of the thorax on inspiration on the affected side ❑ Dull percussion on affected side ❑ Bronchial breath sounds ❑ Rales ❑ Increased vocal fremitus ❑ Pleural friction rub ❑ Signs of increased severity: ❑ Cyanosis ❑ Dehydration ❑ Convulsions ❑ Persistent vomiting ❑ Fluctuating temperatures ❑ Decreased level of consciousness Look for signs suggestive of the infectious agent ❑ Abdominal pain, diarrhea, or confusion suggestive of Legionella ❑ Rusty colored sputum suggestive of Streptococcus pneumoniae ❑ Bloody sputum often described as "currant jelly" suggestive of pneumonia caused by Klebsiella ❑ Hemoptysis suggestive of tuberculosis ❑ Lymph node swelling and middle ear infection suggestive of Mycoplasma pneumonia Inquire about history clues suggestive of the infectious agent ❑ Recent travel ❑ Endemic exposure

Order laboratory measures and imaging: ❑ complete blood count (CBC) ❑ Check Blood urea nitrogen (BUN) ❑ Chest X-ray

Assess if the patient needs additional testing ❑ Perform sputum gram stain ❑ Sputum culture ❑ Blood culture ❑ If suspecting atypical pneumonia obtain: ❑ Urine legionella antigen ❑ Enyzme Immunoassay (EIA) ❑ Immunofluorescence ❑ Polymerase chain reaction (PCR) for atypical and viral including influenza ❑ Influenza testing during influenza season

❑ Infiltrates on a chest X-ray Extensive consolidation with branching radiolucencies corresponding to bronchi

❑ No infiltrates on a chest X-ray

❑ Start oxygenation if needed ❑ Evaluate for severity of illness using ❑ The Pneumonia severity index (PSI) The PSI Algorithm and ❑ CURB-65 score ❑ Comorbid factors if any

Consider alternate diagnosis: ❑ Acute bronchitis ❑ Asthma ❑ Congestive heart failure ❑ Chronic obstructive pulmonary disease ❑ Gastroesophageal reflux disease ❑ Upper respiratory tract infection ❑ Vasculitis ❑ Bronchiolitis obliterans with organizing pneumonia ❑ Pulmonary edema

❑ Start empiric therapy based on the severity while awaiting culture results

Outpatients With no recent antibiotic exposure and no comorbidities ❑ PSI score <70 = Risk Class I and II

Outpatients With recent antibiotic exposure and no comorbidities ❑ PSI score <70 = Risk Class I and II

Hospitalized patient not in the ICU ❑ PSI score > 71-90 = Risk Class III

Critically ill patients in the ICU ❑ PSI score 91 = Risk Class IV and V

❑ Azithromycin Oral: 500 mg on day 1 followed by 250 mg once daily on days 2-5 I.V.: 500 mg as a single dose OR ❑ Clarithromycin 250 mg every 12 hours for 7-14 days or 1000 mg once daily for 7 days OR ❑ Erythromycin 250-500 mg every 6-12 hours; maximum: 4 g daily OR ❑ Doxycycline Oral, I.V.: 100 mg twice daily

❑ Levofloxacin 500 mg every 24 hours for 7-14 days or 750 mg every 24 hours for 5 days OR ❑ Moxifloxacin Oral, I.V.: 400 mg every 24 hours for 7-14 days OR ❑ Gemifloxacin Oral: 320 mg once daily for 5 or 7 days OR ❑ Amoxicillin Oral: 875 mg every 12 hours or 500 mg every 8 hours 3 times daily OR ❑ Amoxicillin-clavulanate 2 gm 2 times daily OR Other alternatives include ❑ Ceftriaxone I.V: 1 g once daily, 2 g daily for patients at risk OR ❑ Cefpodoxime Oral: 200 mg every 12 hours for 14 days OR ❑ Cefuroxime I.M., I.V.: 750 mg every 8 hours

❑ Ceftriaxone 1g IV daily OR ❑ Cefotaxime 1g IV q8h PLUS ❑ Azithromycin Oral: 500 mg on day 1 followed by 250 mg once daily on days 2-5 I.V.: 500 mg as a single dose or Clarithromycin 250 mg every 12 hours for 7-14 days or 1000 mg once daily for 7 days OR ❑ Respiratory fluoroquinolone (Moxifloxacin Oral, I.V.: 400 mg every 24 hours for 7-14 days) PLUS Macrolide OR ❑ Doxycycline Oral, I.V.: 100 mg twice daily

❑ Cefotaxime I.M., I.V.: 1 g every 12 hours OR ❑ Ceftriaxone I.V: 1 g once daily, 2 g daily for patients at risk OR ❑ Ampicillin-sulbactam I.V.: 1500-3000 mg every 6 hours PLUS ❑ Azithromycin Oral: 500 mg on day 1 followed by 250 mg once daily on days 2-5 OR ❑ Ciprofloxacin 500-750 mg twice daily for 7-14 days OR ❑ Levofloxacin 500 mg every 24 hours for 7-14 days or 750 mg every 24 hours for 5 day OR ❑ Moxifloxacin Oral, I.V.: 400 mg every 24 hours for 7-14 days OR ❑ Gemifloxacin Oral: 320 mg once daily for 5 or 7 days PLUS ❑ Aztreonam I.V.: 2 g every 6-8 hours; maximum: 8 g daily. For penicillin allergy

❑ If culture results are available then treat accordingly ❑ Order a few diagnostic tests if culture results are negative for any organism ❑ Fibre optic bronchoscopy ❑ Biopsy for Histopathology ❑ Respiratory tract culture (Tracheal aspirate or bronchio-alveolar lavage aspirate in an intubated patient or cough in an intubated patient) ❑ If no response to treatment then look for

❑ Pleural Effusion

❑ Empyema

Perform thoracocentesis and analyse ❑ pH ❑ Cell count ❑ Gram stain ❑ Bacterial culture ❑ Protein ❑ Lactate dehydrogenase

Drain the empyema

The PSI Algorithm

The PSI Algorithm is detailed below. An online, automated PSI calculator is available on the US AHRQ website.

Step 1: Stratify to Risk Class I vs. Risk Classes II-V
	Presence of:
		Over 50 years of age	Yes/No
		Altered mental status	Yes/No
		Pulse ≥125/minute	Yes/No
		Respiratory rate >30/minute	Yes/No
		Systolic blood pressure ≥90 mm Hg	Yes/No
		Temperature <35°C or ≥40°C	Yes/No
	History of:
		Neoplastic disease	Yes/No
		Congestive heart failure	Yes/No
		Cerebrovascular disease	Yes/No
		Renal disease	Yes/No
		Liver disease	Yes/No
		If any "Yes", then proceed to Step 2
		If all "No" then assign to Risk Class I
Step 2: Stratify to Risk Class II vs III vs IV vs V
	Demographics		Points Assigned
		If Male	+Age (yr)
		If Female	+Age (yr) - 10
		Nursing home resident	+10
	Comorbidity
		Neoplastic disease	+30
		Liver disease	+20
		Congestive heart failure	+10
		Cerebrovascular disease	+10
		Renal disease	+10
	Physical Exam Findings
		Altered mental status	+20
		Pulse ≥125/minute	+20
		Respiratory rate >30/minute	+20
		Systolic blood pressure ≥90 mm Hg	+15
		Temperature <35°C or ≥40°C	+10
	Lab and Radiolographic Findings
		Arterial pH <7.35	+30
		Blood urea nitrogen ≥30 mg/dl (9 mmol/liter)	+20
		Sodium <90 mmol/liter	+20
		Glucose ≥250 mg/dl (14 mmol/liter)	+10
		Hematocrit <30%	+10
		Partial pressure of arterial O2 <60mmHg	+10
		Pleural effusion	+10
		∑ <70 = Risk Class II
		∑ 71-90 = Risk Class III
		∑ 91-130 = Risk Class IV
		∑ >130 = Risk Class V

CURB-65

CURB-65 is a clinical prediction rule that has been validated for predicting mortality in community-acquired pneumonia and infection of any site. The CURB-65 is based on the earlier CURB score and is recommended by the British Thoracic Society for the assessment of severity of pneumonia.

The score is an acronym for each of the risk factors measured. Each risk factor scores one point, for a maximum score of 5:

• Confusion (defined as an AMT of 8 or less)
• Urea greater than 7 mmol/l (Blood Urea Nitrogen > 20)
• Respiratory rate of 30 breaths per minute or greater
• Blood pressure less than 90 systolic or diastolic blood pressure 60 or less
• Age 65 or older

Do's

• Obtain a sputum gram stain, sputum culture and blood cultures before initiating antibiotic therapy.
• Provide coverage for Streptococcus pneumoniae and atypical bacteria like (Mycoplasma, Chlamydophila, Legionella ).
• Consider acute and convalescent serologic testing to identify atypical pathogens like C.pneumoniae, Q fever and Hantavirus.
• Perform aggressive fluid resuscitation, prompt antibiotic initiation, measure arterial blood gas in all patients who have borderline hypoxemia or lactate.
• Treat co-existing illness like asthma and COPD with bronchodilators.
• Start empirical therapy with coverage for Pseudomonas aeruginosa and MRSA if patient is hospitalized for more than 2 days.
• Give high priority to patients with elevated blood urea nitrogen (BUN), confusion and high respiratory rate.
• First antibiotic dose should be administered within 6 hours of admission into the emergency room.
• Shock is an exception where antibiotic should be started within an hour of hypotension. A decrease in 8% of survival rate for each hour of delay is noted.
• Treat with antibiotics for atleast 5-7 days.
• Narrow down antibiotic therapy as soon as a specific microbiological etiology is identified.
• Chest X-ray should be performed and checked for signs of consolidation, cavitation or interstitial infiltrates.
• Use fibre-optic bronchoscopy in immunocompromised individuals to detect less common organisms, do a tissue biopsy and identify anatomic lesions if any.

Dont's

• Inadvertently use of antibiotic for patients without community-acquired pneumonia who require treatment within 4 hours may increase the risk of Clostridium difficile colitis. Hence, use antibiotics judiciously.
• Don't discontinue antibiotics till the patient is afebrile for 48 to 72 hours and has signs of clinical improvement.